N-phenyl imidazole carboxamide inhibitors of 3-phosphoinositide-dependent protein kinase-1

1. A compound of the Formula (I)

wherein:

T is R A , H, C 1 -C 6 alkyl, (C 2 -C 3 alkynylene)-(C 1 -C 6 alkyl), or (C 2 -C 3 alkynylene)-cyclopropyl;

wherein R A is selected from the group consisting of:

(i) 5- to 10-membered mono- or bicyclic heteroaryl wherein said heteroaryl of R A contains one to three heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur;

(ii) 4- to 7-membered monocyclic heterocyclyl wherein said heterocyclyl of R A contains at least one ring nitrogen atom ring member, and optionally one additional heteroatom selected from the group consisting of nitrogen, oxygen, and sulfur;

(iii) 4- to 7-membered monocyclic heterocyclenyl wherein said heterocyclenyl of R A contains one heteroatom selected from the group consisting of nitrogen, oxygen, and sulfur;

(iv) phenyl;

(v) C 3 -C 7 cycloalkyl; and

(vi) C 3 -C 7 cycloalkenyl;

wherein said R A is unsubstituted or substituted by one to three moieties selected from the group consisting of C 1 -C 3 alkyl, C 1 -C 3 alkoxy, halo, C 1 -C 3 fluoroalkyl, hydroxy, amino, C 1 -C 6 alkylamino,

C 1 -C 6 dialkylamino, C 1 -C 6 hydroxyalkyl, C 1 -C 6 alkylamino, cyano, —C(O)—(C 1 -C 6 alkyl), —C(O)—O—(C 1 -C 6 alkyl), sulfonamido, —N(H)—C(O)—(C 1 -C 6 alkyl), benzylamino, —Y—R 9 , and —C(O)—N(R 11 ) 2 ;

Y is a bond, C 1 -C 3 alkylene, —O—, —N(H)—, or —N(H)—(C 1 -C 3 alkylene), wherein said C 1 -C 3 alkylene or —N(H)—(C 1 -C 3 alkylene) of Y is unsubstituted or substituted by C 1 -C 3 hydroxyalkyl;

R 9 is

 (i) phenyl;

 (ii) 5- to 6-membered heteroaryl, wherein said heteroaryl of R 9 contains one to two heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur; or

 (iii) C 3 -C 7 cycloalkyl;

wherein said R 9 is unsubstituted or substituted by one to two C 1 -C 3 alkyl, C 1 -C 3 alkoxy, halo, or C 1 -C 3 fluoroalkyl;

each R 11 is independently H, C 1 -C 6 alkyl, -(C 1 -C 3 alkylene)-N(C 1 -C 3 alkyl) 2 , —(C 1 -C 3 alkylene)-R B , or optionally, the R 11 groups together with the nitrogen atom to which they are attached, form a 5- to 6-membered heterocyclyl containing one to two nitrogen atoms, which is heterocyclyl is optionally substituted by C 1 -C 3 alkyl;

 wherein R B is phenyl, pyridinyl, pyrimidinyl, pyrazinyl, or pyridazinyl, wherein said R B is unsubstituted or substituted by one to two C 1 -C 3 alkyl, C 1 -C 3 alkoxy, halo, or C 1 -C 3 fluoroalkyl;

R 6 is H, 2 H, C 1 -C 3 alkyl, or C 1 -C 3 alkoxy;

D is

(i) —(C 1 -C 3 dialkylamino)-(C 1 -C 3 alkoxy);

(ii) —C(O)—N(H)-heterocyclyl wherein said heterocyclyl moiety is a 5- to 6-membered ring containing one to two nitrogen atoms, and is unsubstituted or substituted by one to two C 1 -C 3 alkyl, C 1 -C 3 alkoxy, halo, or phenyl;

(iii) a group of the formula

wherein

n is 0, 1, or 2;

R 4 , R 5 and R 10 are independently H, C 1 -C 3 alkyl, fluoro, hydroxy, amino, C 1 -C 3 alkylamino, C 1 -C 3 dialkylamino, ureido, azetidinyl, pyrrolidinyl, piperidino, pyrazolyl, —(C 1 -C 3 )alkylene-OH,

-M-N(R 7 )(R 8 ), or —N(R 7 )—C(O)(R 8 );

 M is

 (i) a direct bond;

 (ii) —C(O)—;

 (iii) —(C 1 -C 3 alkylene)-C(O)—;

 (iv) C 1 -C 3 alkylene; or

 (v) a ring of the formula E

wherein o is 1, 2, 3, or 4;

 wherein ring E or said alkylene of M is unsubstituted or substituted by one to two C 1 -C 3 alkyl;

R 7 and R 8 are independently selected from the group consisting of H, C 1 -C 3 alkyl, (C 1 -C 6 alkylene)-NH 2 , (C 1 -C 6 alkylene)-N(H)(C 1 -C 3 alkyl), (C 1 -C 6 alkylene)-N(C 1 -C 3 alkyl) 2 , (C 3 -C 6 cycloalkyl)-NH 2 , (C 1 -C 3 alkylene)-(C 3 -C 6 cycloalkyl)-NH 2 , (3,3,3-trifluoro-2-hydroxy)propyl, and C 1 -C 3 alkanoyl;

or optionally, wherein R 4 , R 5 , or R 10 is -M-N(R 7 )(R 8 ), R 7 and R 8 together with the nitrogen atom to which it is attached form

(i) R C , wherein R C is a 4- to 10-membered mono- or bicyclic heterocyclyl containing one nitrogen atom and one additional heteroatom selected from the group consisting of nitrogen, oxygen and sulfur, and wherein R C is unsubstituted or substituted by 1 to 4 R 15 moieties; or

(ii) R D , wherein R D is a 4- to 10-membered mono- or bicyclic heterocyclyl containing one nitrogen atom and wherein R D is substituted by R 16 , and wherein R D is optionally and additionally substituted by 1 to 3 R 15 ;

 wherein each R 15 is independently selected from the group consisting of C 1 -C 3 alkyl, fluoro, C 1 -C 3 trifluoroalkyl, (C 1 -C 3 alkylene)-OH, (C 1 -C 3 alkylene)-NH 2 , and (C 1 -C 3 alkylene)-C(O)NH 2 , or optionally two R 15 moieties together with the carbon atom to which they are attached form a carbonyl;

 wherein R 16 is selected from the group consisting of (C 1 -C 3 alkylene)-OH, (C 1 -C 3 alkylene)-NH 2 , and (C 1 -C 3 alkylene)- C(O)NH 2 ;

or two of R 4 , R 5 and R 10 together with the carbon atom(s) to which they are attached form a 5- or 6-membered cycloalkyl or heterocyclyl ring containing one to two heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur;

R 14 is H or C 1 -C 3 alkyl;

R 1 , R 2 and R 3 are independently selected from the group consisting of H, 2 H, halo, C 1 -C 3 alkyl, amino, C 1 -C 3 alkylamino, C 1 -C 3 dialkylamino, carbamyl, hydroxy, cyano, trifluoromethyl, C 3 -C 7 cycloalkyl, and 5- to 6-membered heteroaryl containing one or two heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur;

or a pharmaceutically acceptable salt thereof.

2. The compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein R 6 is H.

3. The compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein D is

wherein

M is a direct bond, —C(O)—, or methylene;

R 4 and R 5 are independently selected from the group consisting of H, C 1 -C 3 alkyl, and fluoro, and

R 7 and R 8 are independently selected from the group consisting of H, C 1 -C 3 alkyl, —CH 2 CH 2 NH 2 , —CH 2 CH 2 NHCH 2 CH 3 , —CH 2 CH 2 CH 2 CH 2 NHCH 3 , cyclohexylamino,

or optionally R 7 and R 8 together with the nitrogen atom to which it is attached form:

(i) R C , wherein R C is a 4- to 10-membered mono- or bicyclic heterocyclyl containing one nitrogen atom and one additional heteroatom selected from the group consisting of nitrogen, oxygen and sulfur, and wherein R C is unsubstituted or substituted by 1 to 4 R 15 moieties; or

(ii) R D , wherein R D is a 4- to 10-membered mono- or bicyclic heterocyclyl containing one nitrogen atom and wherein R D is substituted by R 16 , and wherein R D is optionally and additionally substituted by 1 to 3 R 5 ;

wherein each R 15 is independently selected from the group consisting of C 1 -C 3 alkyl, fluoro, C 1 -C 3 trifluoroalkyl, (C 1 -C 3 alkylene)-OH, (C 1 -C 3 alkylene)-NH 2 , and (C 1 -C 3 alkylene)-C(O)NH 2 , or optionally two R 15 moieties together with the carbon atom to which they are attached form a carbonyl;

wherein R 16 is selected from the group consisting of (C 1 -C 3 alkylene)-OH, (C 1 -C 3 alkylene)-NH 2 , and (C 1 -C 3 alkylene)-C(O)NH 2 .

4. The compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein D is selected from the group consisting of:

5. The compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein T is selected from the group consisting of

H and

R A ; wherein R A is selected from the group consisting of cyclopropyl, phenyl, pyrazolyl, thienyl, pyridinyl, pyrimidinyl, pyridazinyl, indolyl, piperidinyl, piperazinyl, and dihydropyranyl, wherein R A is unsubstituted or substituted by one to three moieties selected from the group consisting of C 1 -C 3 alkyl, C 1 -C 3 alkoxy, halo, trifluoromethyl, hydroxy, amino, C 1 -C 6 alkylamino, C 1 -C 6 dialkylamino, C 1 -C 6 hydroxyalkyl, cyano, —C(O)—(C 1 -C 6 alkyl), —C(O)—O—(C 1 -C 6 alkyl), sulfonamido, —N(H)—C(O)—(C 1 -C 6 alkyl), benzylamino, —Y—R 9 , and —C(O)N(R 11 ) 2 .

6. The compound of claim 5 or a pharmaceutically acceptable salt thereof, wherein T is selected from the group consisting of:

7. The compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein:

T is R A , wherein R A is selected from the group consisting of substituted or unsubstituted cyclopropyl, phenyl, pyrazolyl, pyridinyl, pyrimidinyl, indolyl, piperidinyl, piperazinyl, and dihydropyranyl, wherein R A is unsubstituted or substituted by one to three moieties selected from the group consisting of C 1 -C 3 alkyl, C 1 -C 3 alkoxy, halo, trifluoromethyl, hydroxy, amino, C 1 -C 6 alkylamino, C 1 -C 6 dialkylamino, C 1 -C 6 hydroxyalkyl, sulfonamido,

—N(H)—C(O)—(C 1 -C 3 alkyl), benzylamino, —Y—R 9 , and —C(O)N(R 11 ) 2 ;

D is

M is a direct bond, —C(O)—, or methylene;

R 4 and R 5 are independently selected from the group consisting of H, C 1 -C 3 alkyl, and fluoro;

R 7 and R 8 are independently selected from the group consisting of H, C 1 -C 3 alkyl, —CH 2 CH 2 NH 2 , —CH 2 CH 2 NHCH 2 CH 3 , —CH 2 CH 2 CH 2 CH 2 NHCH 3 , cyclohexylamino,

or optionally R 7 and R 8 together with the nitrogen atom to which it is attached form:

(i) R C , wherein R C is a 4- to 10-membered mono- or bicyclic heterocyclyl containing one nitrogen atom and one additional heteroatom selected from the group consisting of nitrogen, oxygen and sulfur, and wherein R C is unsubstituted or substituted by 1 to 4 R 15 moieties; or

(ii) R D , wherein R D is a 4- to 10-membered mono- or bicyclic heterocyclyl containing one nitrogen atom and wherein R D is substituted by R 16 , and wherein R D is optionally and additionally substituted by 1 to 3 R 15 ;

wherein each R 15 is independently selected from the group consisting of C 1 -C 3 alkyl, fluoro, C 1 -C 3 trifluoroalkyl, (C 1 -C 3 alkylene)-OH, (C 1 -C 3 alkylene)-NH 2 , and (C 1 -C 3 alkylene)-C(O)NH 2 , or optionally two R 15 moieties together with the carbon atom to which they are attached form a carbonyl;

wherein R 16 is selected from the group consisting of (C 1 -C 3 alkylene)-OH, (C 1 -C 3 alkylene)-NH 2 , and (C 1 -C 3 alkylene)-C(O)NH 2 ;

R 6 is H; and

R 1 , R 2 , and R 3 are independently selected from the group consisting of H, fluoro, and pyrazolyl.

8. The compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein R 1 , R 2 , and R 3 are independently selected from the group consisting of H, halo, and pyrazolyl.

9. The compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein the compound has the Formula (Ia):

X is CH or N;

R 12 and R 13 are independently selected from the group consisting of H, C 1 -C 3 alkyl, amino, C 1 -C 3 alkylamino, carbamyl, hydroxymethyl, benzylamino, 4-fluorobenzylamino, 3,4-difluorobenzylamino, 4-trifluorobenzylamino, 3,4-dimethoxybenzylamino, and 2-hydroxy-1- phenylethylamino;

R 1 is H or halo;

M is a direct bond or methylene; and

R 7 and R 8 are independently H or C 1 -C 3 alkyl.

10. The compound of claim 9 or a pharmaceutically acceptable salt thereof, wherein the moiety

is selected from the group consisting of

11. The compound of claim 9 or a pharmaceutically acceptable salt thereof wherein the moiety

is selected from the group consisting of

12. A compound selected from one of the following compounds:

N-[5-amino-2-(3(R)-amino-1-piperidinyl)phenyl]-1H-imidazole-2-carboxamide;

1-[4-amino-2-[(1H-imidazol-2-ylcarbonyl)amino]phenyl]-4-(methylamino)-4-piperidinecarboxamide;

N-[5-amino-2-[4-(aminomethyl)-1-piperidinyl]phenyl]-1H-imidazole-2-carboxamide;

N-[2-(3(R)-amino-1-piperidinyl)-3-fluorophenyl]-4-[1-(phenylmethyl)-1H-pyrazol-4-yl]-1H-imidazole-2-carboxamide;

N-[2-(3(R)-amino-1-piperidinyl)-3-fluorophenyl]-4-[1-(2-thienylmethyl)-1H-pyrazol-4-yl]-1H-imidazole-2-carboxamide;

N-[2-[2-(dimethylamino)ethoxy]phenyl]-4-[1-(phenylmethyl)-1H-pyrazol-4-yl]-1H-imidazole-2-carboxamide;

N-[2-(3(R)-amino-1-piperidinyl)-3-fluorophenyl]-4-[1-(2-pyridinylmethyl)-1H-pyrazol-4-yl]-1H-imidazole-2-carboxamide;

N-[2-(3(R)-amino-1-piperidinyl)-3-fluorophenyl]-4-(2-methyl-4-pyridinyl)-1H-imidazole-2- carboxamide;

N-[2-(3(R)-amino-1-piperidinyl)-3-fluorophenyl]-4-[5-(trifluoromethyl)-3-pyridinyl]-1H-imidazole-2-carboxamide;

N-[2-(3(R)-amino-1-piperidinyl)-3-fluorophenyl]-4-(4-pyridinyl)-1H-imidazole-2-carboxamide;

N-[2-(3(R)-amino-1-piperidinyl)-3-fluorophenyl]-4-(1H-pyrazol-4-yl)-1H-imidazole-2-carboxamide;

N-[2-(3(R)-amino-1-piperidinyl)-3-fluorophenyl]-4-bromo-1H-imidazole-2-carboxamide;

N-[2-(3(R)-amino-1-piperidinyl)-3-fluorophenyl]-4-[1-(3-pyridinylmethyl)-1H-pyrazol-4-yl]-1H-imidazole-2-carboxamide;

N-[2-(3(R)-amino-1-piperidinyl)-3-fluorophenyl]-4-(1-methyl-1H-pyrazol-4-yl)-1H-imidazole-2-carboxamide;

N-[2-[3(R)-[(aminocarbonyl)amino]-1-piperidinyl]-3-fluorophenyl]-4-bromo-1H-imidazole-2-carboxamide;

N-[5-amino-2-(3(R)-amino-1-piperidinyl)phenyl]-4-bromo-1H-imidazole-2-carboxamide;

N-[2-[2-(dimethylamino)ethoxy]phenyl]-4-(1H-indo1-3-yl)-1H-imidazole-2-carboxamide;

N-[2-[4-(aminomethyl)-1-piperidinyl]-3-fluorophenyl]-4-(2-methyl-4-pyridinyl)-1H-imidazole-2-carboxamide;

N-[2-(3(R)-amino-1-piperidinyl)-3-fluorophenyl]-4-[2-(trifluoromethyl)-4-pyridinyl]-1H-imidazole-2-carboxamide;

N-[2-(-3(R)-amino-1-piperidinyl)-3-fluorophenyl]-4-(2-amino-4-pyridinyl)-1H-imidazole-2-carboxamide;

N-[2-(3(R)-amino-1-piperidinyl)-3-fluorophenyl]-4-(2-methoxy-4-pyridinyl)-1H-imidazole-2-carboxamide;

N-[2-(3(R)-amino-1-piperidinyl)-3-fluorophenyl]-4-(3,6-dihydro-2h-pyran-4-yl)-1H-imidazole-2-carboxamide;

N-[2-(3(R)-amino-1-piperidinyl)-3-fluorophenyl]-4-(2-cyclopropyl-4-pyridinyl)-1H-imidazole-2-carboxamide;

4-(2-amino-6-methyl-4-pyridinyl)-N-[2-(3(R)-amino-1-piperidinyl)-3-fluorophenyl]-1H-imidazole-2-carboxamide;

N-[2-(3(R)-amino-1-piperidinyl)-3-fluorophenyl]-4-(2-hydroxy-4-pyridinyl)-1H-imidazole-2-carboxamide;

N-[2-(3(R)-amino-1-piperidinyl)-3-fluorophenyl]-4-[2-(hydroxymethyl)-4-pyridinyl]-1H-imidazole-2-carboxamide;

N-[2-[4-(aminomethyl)-1-piperidinyl]-3-fluorophenyl]-4-(2-amino-4-pyridinyl)-1H-imidazole-2-carboxamide;

N-[2-[4-(aminomethyl)-1-piperidinyl]-3,4-difluorophenyl]-4-(2-amino-4-pyridinyl)-1H-imidazole-2-carboxamide;

4-(2-amino-6-methyl-4-pyrimidinyl)-N-[2-(3(R)-amino-1-piperidinyl)-3-fluorophenyl]-1H-imidazole-2-carboxamide;

N-[2-[4-(aminomethyl)-1-piperidinyl]-3-fluorophenyl]-4-(2-ethyl-4-pyridinyl)-1H-imidazole-2-carboxamide;

N-[2-[4-(aminomethyl)-1-piperidinyl]-3-fluorophenyl]-4-[3-(aminosulfonyl)phenyl]-1H-imidazole-2-carboxamide;

N-[2-[4-(aminomethyl)-1-piperidinyl]-3-fluorophenyl]-4-[2-(methylamino)-4-pyridinyl]-1H-imidazole-2-carboxamide;

4-[2-(acetylamino)-4-pyridinyl]-N-[2-[4-(aminomethyl)-1-piperidinyl]-3-fluorophenyl]-1H-imidazole-2-carboxamide;

N-[2-[4-(aminomethyl)-1-piperidinyl]-3-fluorophenyl]-4-(3-chlorophenyl)-1H-imidazole-2-carboxamide;

N-[2-[4-(aminomethyl)-1-piperidinyl]-3-fluorophenyl]-4-[2-[(phenylmethyl)amino]-4-pyridinyl]-1H-imidazole-2-carboxamide;

N-[2-[4-(aminomethyl)-1-piperidinyl]-3-fluorophenyl]-4-[2-(dimethylamino)-4-pyridinyl]-1H-imidazole-2-carboxamide;

N-[2-[4-(aminomethyl)-1-piperidinyl]-3-fluorophenyl]-4-(2,5-dimethylphenyl)-1H-imidazole-2-carboxamide;

N-[2-(3(R)-amino-1-piperidinyl)-3-fluorophenyl]-4-(2,4-difluorophenyl)-1H-imidazole-2-carboxamide;

N-[2-(3(R)-amino-1-piperidinyl)-3-fluorophenyl]-4-[2-(1H-pyrazol-1-yl)-4-pyridinyl]-1H-imidazole-2-carboxamide;

4-(2-amino-4-pyridinyl)-N-[2-[4-[(dimethylamino)methyl]-1-piperidinyl]phenyl]-1H-imidazole-2-carboxamide;

N-[2-[4-(aminomethyl)-1-piperidinyl]-3-fluorophenyl]-4--[3-(2-hydroxyethyl)phenyl]-1H-imidazole-2-carboxamide;

N-[2-[4-(aminomethyl)-1-piperidinyl]-3-fluorophenyl]-4-[2-(cyclopropylamino)-4-pyridinyl]-1H-imidazole-2-carboxamide;

N-[3-fluoro-2-(octahydro-6h-pyrrolo[2,3-c]pyridin-6-yl)phenyl]-4-(2-methyl-4-pyridinyl)-1H-imidazole-2-carboxamide;

N-[2-[4-(aminomethyl)-1-piperidinyl]-3-fluorophenyl]-4-(6-cyano-2-pyridinyl)-1H-imidazole-2-carboxamide;

4-(5-acetyl-2-thienyl)-N-[2-[4-(aminomethyl)-1-piperidinyl]-3-fluorophenyl]-1H-imidazole-2-carboxamide;

N-[2-(2,9-diazaspiro[5.5]undec-9-yl)-3-fluorophenyl]-4-(2-methyl-4-pyridinyl)-1H-imidazole-2-carboxamide;

N-[2-[4-(aminomethyl)-1-piperidinyl]-3-fluorophenyl]-4-(2-amino-6-methyl-4-pyrimidinyl)-1H-imidazole-2-carboxamide;

N-[2-[4-(aminomethyl)-1-piperidinyl]-3-fluorophenyl]-4-[3-(trifluoromethyl)-1H-pyrazol-5-yl]-1H-imidazole-2-carboxamide;

N-[2-[4-(aminomethyl)-1-piperidinyl]-3-fluorophenyl]-4-(6-amino-2-methyl-4-pyrimidinyl)-1H-imidazole-2-carboxamide;

N-[2-[4-[(dimethylamino)methyl]-1-piperidinyl]-3-fluorophenyl]-4-(2-methyl-4-pyridinyl)-1H-imidazole-2-carboxamide;

N-[2-[4-(aminomethyl)-1-piperidinyl]-5-(1H-pyrazol-4-yl)phenyl]-4-(1H-pyrazol-4-yl)-1H-imidazole-2-carboxamide;

N-[2-[4-(aminomethyl)-4-ethyl-1-piperidinyl]-3-fluorophenyl]-4-(2-methyl-4-pyridinyl)-1H-imidazole-2-carboxamide;

N-[2-[4-(aminomethyl)-1-piperidinyl]-3-fluorophenyl]-4-(1H-pyrazol-4-yl)-1H-imidazole-2-carboxamide;

N-[2-(3,8-diazabicyclo [3.2.1]oct-3-yl)-3-fluorophenyl]-4-(2-methyl-4-pyridinyl)-1H-imidazole-2-carboxamide;

N-[2-[4-(aminomethyl)-4-methyl-1-piperidinyl]-3-fluorophenyl]-4-(2-methyl-4-pyridinyl)-1H-imidazole-2-carboxamide;

methyl 3-[2-[[[2-[4-(aminomethyl)-1-piperidinyl]-3-fluorophenyl]amino]carbonyl]-1H-imidazol-4-yl]benzoate;

N-[3-fluoro-2-[4-[(methylamino)methyl]-1-piperidinyl]phenyl]-4-(2-methyl-4-pyridinyl)-1H-imidazole-2-carboxamide;

N-[3-fluoro-2-(hexahydropyrrolo [3,4-c]pyrrol-2(1H)-yl)phenyl]-4-(2-methyl-4-pyridinyl)-1H-imidazole-2-carboxamide;

1-[2-fluoro-6-[[[4-(2-methyl-4-pyridinyl)-1H-imidazol-2-yl]carbonyl]amino]phenyl]-N-methyl-4-piperidinecarboxamide;

N-ethyl-1-[2-fluoro-6-[[[4-(2-methyl-4-pyridinyl)-1H-imidazol-2-yl]carbonyl]amino]phenyl]-4-piperidinecarboxamide;

1-[2-fluoro-6-[[[4-(2-methyl-4-pyridinyl)-1H-imidazol-2-yl]carbonyl]amino]phenyl]-N,N-dimethyl-4-piperidinecarboxamide;

1-[2-fluoro-6-[[[4-(2-methyl-4-pyridinyl)-1H-imidazol-2-yl]carbonyl]amino]phenyl]-N-(3,3,3-trifluoro-2-hydroxypropyl)-4-piperidinecarboxamide;

N-[2-[4-(aminomethyl)-1-piperidinyl]-3-fluorophenyl]-4-5-pyrimidinyl)-1H-imidazole-2-carboxamide;

N-[3-fluoro-2-[4-[(3(S)-fluoro-1-pyrrolidinyl)carbonyl]-1-piperidinyl]phenyl]-4-(2-methyl-4-pyridinyl)-1H-imidazole-2-carboxamide;

1-[2-fluoro-6-[[[4-(2-methyl-4-pyridinyl)-1H-imidazol-2-yl]carbonyl]amino]phenyl]-N-(1(R)-phenylethyl)-4-piperidinecarboxamide;

N-[2-[4-(1-azetidinylcarbonyl)-1-piperidinyl]-3-fluorophenyl]-4-(2-methyl-4-pyridinyl)-1H-imidazole-2-carboxamide;

N-[2-[4-(1-amino-1-methylethyl)-1-piperidinyl]-3-fluorophenyl]-4-(2-methyl-4-pyridinyl)-1H-imidazole-2-carboxamide;

6-[2-[[[2-[4-(aminomethyl)-1-piperidinyl]-3-fluorophenyl]amino]carbonyl]-1H-imidazol-4-yl]-2-hydroxy-4-pyrimidinecarboxamide;

N-[2-[4-(aminomethyl)-1-piperidinyl]-3-fluorophenyl]-4-[2-amino-6-[(phenylmethyl)amino]-4-pyrimidinyl]-1H-imidazole-2-carboxamide;

N-[2-[4-(aminomethyl)-1-piperidinyl]-3-fluorophenyl]-4-[2-amino-6-[[[4-(trifluoromethyl)phenyl]methyl]amino]-4-pyrimidinyl]-1H-imidazole-2-carboxamide;

4-[2-amino-6-[[(4-fluorophenyl)methyl]amino]-4-pyrimidinyl]-N-[2-[4-(aminomethyl)-1-piperidinyl]-3-fluorophenyl]-1H-imidazole-2-carboxamide;

4-[2-amino-6-[[2-hydroxy-1(R)-phenylethyl]amino]-4-pyrimidinyl]-N-[2-[4-(aminomethyl)-1-piperidinyl]-3-fluorophenyl]-1H-imidazole-2-carboxamide;

N-[2-[4-(aminomethyl)-1-piperidinyl]-3-fluorophenyl]-4-[6-[[(4-fluorophenyl)methyl]amino]-4-pyrimidinyl]-1H-imidazole-2-carboxamide;

N-[2-[4-(aminomethyl)-1-piperidinyl]-3-fluorophenyl]-4-[6-[[(3,4-difluorophenyl)methyl]amino]-4-pyrimidinyl]-1H-imidazole-2-carboxamide;

4-[2-amino-6-[[(3,4-difluorophenyl)methyl]amino]-4-pyrimidinyl]-N-[2-[4-(aminomethyl)-1-piperidinyl]-3-fluorophenyl]-1H-imidazole-2-carboxamide;

4-[2-amino-6-[[(3 ,4-dimethoxyphenyl)methyl]amino]-4-pyrimidinyl]-N-[2-[4-(aminomethyl)-1-piperidinyl]-3-fluorophenyl]-1H-imidazole-2-carboxamide;

4-[2-amino-6-[(2-hydroxy-1(S)-phenylethyl)amino]-4-pyrimidinyl]-N-[2-[4-(aminomethyl)-1-piperidinyl]-3-fluorophenyl]-1H-imidazole-2-carboxamide;

N-[3-fluoro-2-[4-(8-oxa-3-azabicyclo [3.2.1]oct-3-ylcarbonyl)-1-piperidinyl]phenyl]-4-(2-methyl-4-pyridinyl)-1H-imidazole-2-carboxamide;

N-[3-fluoro-2-[4-(2-oxa-5-azabicyclo [2.2.1]hept-5-ylcarbonyl)-1-piperidinyl]phenyl]-4-(2-methyl-4-pyridinyl)-1H-imidazole-2-carboxamide;

N-[3-fluoro-2-[4-[[3-(hydroxymethyl)-4-morpholinyl]carbonyl]-1-piperidinyl]phenyl]-4-(2-methyl-4-pyridinyl)-1H-imidazole-2-carboxamide;

N-[2-[4-[[3-(aminomethyl)-4-morpholinyl]carbonyl]-1-piperidinyl]-3-fluorophenyl]-4-(2-methyl-4-pyridinyl)-1H-imidazole-2-carboxamide;

1-[2-fluoro-6-[[[4-(2-methyl-4-pyridinyl)-1H-imidazol-2-yl]carbonyl]amino]phenyl]-4-piperidinecarboxamide;

N-(2-aminoethyl)-1-[2-fluoro-6-[[[4-(2-methyl-4-pyridinyl)-1H-imidazol-2-yl]carbonyl]amino]phenyl]-4-piperidinecarboxamide;

N-(2-aminocyclohexyl)-1-[2-fluoro-6-[[[4-(2-methyl-4-pyridinyl)-1H-imidazol-2-yl]carbonyl]amino]phenyl]-4-piperidinecarboxamide;

1-[2-fluoro-6-[[[4-(2-methyl-4-pyridinyl)-1H-imidazol-2-yl]carbonyl]amino]phenyl]-N-[4-(methylamino)butyl]-4-piperidinecarboxamide;

N-[2-(ethylamino)ethyl]-1-[2-fluoro-6-[[[4-(2-methyl-4-pyridinyl)-1H-imidazol-2-yl]carbonyl]amino]phenyl]-4-piperidinecarboxamide;

N-[2-[4-(3,8-diazabicyclo[3.2.1]oct-8-ylcarbonyl)-1-piperidinyl]-3-fluorophenyl]-4-(2-methyl-4-pyridinyl)-1H-imidazole-2-carboxamide;

N-[(1-aminocyclopentyl)methyl]-1-[2-fluoro-6-[[[4-(2-methyl-4-pyridinyl)-1H-imidazol-2-yl]carbonyl]amino]phenyl]-4-piperidinecarboxamide;

N-[2-[4-[[2-(aminomethyl)-4-morpholinyl]carbonyl]-1-piperidinyl]-3-fluorophenyl]-4-(2-methyl-4-pyridinyl)-1H-imidazole-2-carboxamide;

N-[3-fluoro-2-[4-[[2-(2-hydroxyethyl)-4-morpholinyl]carbonyl]-1-piperidinyl]phenyl]-4-(2-methyl-4-pyridinyl)-1H-imidazole-2-carboxamide;

N-[2-[4-(3,6-diazabicyclo[3.2.1]oct-3-ylcarbonyl)-1-piperidinyl]-3-fluorophenyl]-4-(2-methyl-4-pyridinyl)-1H-imidazole-2-carboxamide;

N-[3-fluoro-2-[4-[(3(R)-fluoro-l-pyrrolidinyl)carbonyl]-1-piperidinyl]phenyl]-4-(2-methyl-4-pyridinyl)-1H-imidazole-2-carboxamide;

N-[3-fluoro-2-[4-[(3-oxo-2,8-diazaspiro[4.5]dec-8-yl)carbonyl]-1-piperidinyl]phenyl]-4-(2-methyl-4-pyridinyl)-1H-imidazole-2-carboxamide;

N-[2-[4-(2,7-diazaspiro[3.5]noN-7-ylcarbonyl)-1-piperidinyl]-3-fluorophenyl]-4-(2-methyl-4-pyridinyl)-1H-imidazole-2-carboxamide;

N-[2-[4-[[2-(1-aminoethyl)-4-morpholinyl]carbonyl]-1-piperidinyl]-3-fluorophenyl]-4-(2-methyl-4-pyridinyl)-1H-imidazole-2-carboxamide;

N-[3-fluoro-2-[4-[[4-hydroxy-4-(2-pyridinyl)-1-piperidinyl]carbonyl]-1-piperidinyl]phenyl]-4-(2-methyl-4-pyridinyl)-1H-imidazole-2-carboxamide;

N-(2-(4-(aminomethyl)piperidin-1-yl)-3-fluorophenyl)-4-1-(difluoromethyl)-6-oxo-1,6-dihydropyridin-3-yl)-1H-imidazole-2-carboxamide;

(R)-N-(2-(3-aminopiperidin-1-yl)-3-fluorophenyl)-4-(2-chloro-6-methylpyridin-4-yl)-1H-imidazole-2-carboxamide;

4-(2-amino-6-morpholinopyrimidin-4-yl)-N-(2-(4-(aminomethyl)piperidin-1-yl)-3-fluorophenyl)-1H-imidazole-2-carboxamide;

methyl 4-(6-(2-(2-(4-(aminomethyl)piperidin-1-yl)-3-fluorophenylcarbamoyl)-1H-imidazol- 4-yl)-2-(methylamino)pyrimidin-4-yl)piperazine-1-carboxylate;

4-(6-(4-acetylpiperazin-1-yl)-2-(methylamino)pyrimidin-4-yl)-N-(2-(4-(aminomethyl)piperidin-1-yl)-3-fluorophenyl)-1H-imidazole-2-carboxamide;

N-cyclohexyl-6-methyl-1-(2-(methylamino)-6-(2-(2-(piperazin-1-yl)phenylcarbamoyl)-1H-imidazol-4-yl)pyrimidin-4-yl)piperidine-3-carboxamide;

4-(6-(4-acetylpiperazine-1-yl)-2-(methylamino)pyrimidin-4-yl)-N-(2-(piperazin-1-yl)phenyl)-1H-imidazole-2-carboxamide;

N-cyclohexyl-6-methyl-1-(2-(methylamino)-6-(2-(2-(piperazin-1-yl)phenylcarbamoyl)-1H-imidazol-4-yl)pyrimidin-4-yl)piperidine-3-carboxamide;

benzyl 4-(2-(methylamino)-6-(2-(2-(piperazin-1-yl)phenylcarbamoyl)-1H-imidazol-4-yl)pyrimidin-4-yl)piperazine-1-carboxylate;

N-cyclohexyl-4-(2-(methylamino)-6-(2-(2-(piperazin-1-yl)phenylcarbamoyl)-1H-imidazol-4-yl)pyrimidin-4-yl)morpholine-2-carboxamide;

1-(6-(2-(2-(4-(aminomethyl)piperidin-1-yl)-3-fluorophenylcarbamoyl)-1H-imidazol-4-yl)-2-(methylamino)pyrimidin-4-yl)-N-cyclohexyl-6-methylpiperidine-3-carboxamide;

N-cyclohexyl-1-(6-(2-(3-fluoro-2-morpholinophenylcarbamoyl)-1H-imidazol-4-yl)-2-(methylamino)pyrimidin-4-yl)-6-methylpiperidine-3-carboxamide;

1-(6-(2-(2-((S)-2-(aminomethyl)morpholino)-3-fluorophenylcarbamoyl)-1H-imidazol-4-yl)-2-(methylamino)pyrimidin-4-yl)-N-cyclohexyl-6-methylpiperidine-3-carboxamide;

1-(6-(2-(2-((R)-2-(aminomethyl)morpholino)-3-fluorophenylcarbamoyl)-1H-imidazol-4-yl)-2-(methylamino)pyrimidin-4-yl)-N-cyclohexyl-6-methylpiperidine-3-carboxamide;

1-(2-amino-6-(2-(5-amino-2-(2,9-diazaspiro [5.5]undecan-9-yl)phenylcarbamoyl)-1H-imidazol-4-yl)pyrimidin-4-yl)-N-cyclohexyl-6-methylpiperidine-3-carboxamide;

1-(6-(2-(2-(1 ,4-dioxa-8-azaspiro [4.5]decan-8-yl)phenylcarbamoyl)-1H-imidazol-4-yl)-2-(methylamino)pyrimidin-4-yl)-N-cyclohexyl-6-methylpiperidine-3-carboxamide;

1-(6-(2-(2-((R)-3-aminopiperidin-1-yl)-3fluorophenylcarbamoyl)-1H-imidazol-4-yl)-2-(methylamino)pyrimidin-4-yl)-N-cyclohexyl-6-methylpiperidine-3-carboxamide;

(3S,6R)-1-(6-(2-(2-(4-(aminomethyl)piperidin-1-yl)-3-fluorophenylcarbamoyl)-1H-imidazol-4-yl)-2-(methylamino)pyrimidin-4-yl)-N-cyclohexyl-6-methylpiperidine-3-carboxamide;

(3R,6S)-1-(6-(2-(2-(4-(aminomethyl)piperidin-1-yl)-3-fluorophenylcarbamoyl)-1H-imidazol- 4-yl)-2-(methylamino)pyrimidin-4-yl)-N-cyclohexyl-6-methylpiperidine-3-carboxamide;

(3S,6R)-1-(6-(2-(2-((S)-2-(aminomethyl)morpholino)-3-fluorophenylcarbamoyl)-1H-imidazol-4-yl)-2-(methylamino)pyrimidin-4-yl)-N-cyclohexyl-6-methylpiperidine-3-carboxamide;

N-cyclohexyl-1-(6-(2-(3-fluoro-2-(2,7-diazaspiro [3.5]nonan-7-yl)phenylcarbamoyl)-1H-imidazol-4-yl)-2-(methylamino)pyrimidin-4-yl)-6-methylpiperidine-3-carboxamide;

N-cyclohexyl-1-(6-(2-(3-fluoro-2-(2,8-diazaspiro [4.5]decan-8-yl)phenylcarbamoyl)-1H-imidazol-4-yl)-2-(methylamino)pyrimidin-4-yl)-6-methylpip eridine-3-carboxamide;

(R)-N-(2-(4-(aminomethyl)piperidin-1-yl)-3-fluorophenyl)-4-(2-(methylamino)-6-(2-methylpiperazin-1-yl)pyrimidin-4-yl)-1H-imidazole-2-carboxamide;

(R)-N-(2-(4-(aminomethyl)piperidin-1-yl)-3-fluorophenyl)-4-(2-(methylamino)-6-(3-methylmorpholino)pyrimidin-4-yl)-1H-imidazole-2-carboxamide;

N-cyclohexyl-1-(6-(2-(3-fluoro-2-(R)-3-methylmorpholino)phenylcarbamoyl)-1H-imidazol-4-yl)-2-(methylamino)pyrimidin-4-yl)-6-methylpiperidine-3-carboxamide;

(R)-4-(6-(2-(aminomethyl)morpholino)-2-(methylamino)pyrimidin-4-yl)-N-(2-(4-(aminomethyl)piperidin-1-yl)-3-fluorophenyl)-1H-imidazole-2-carboxamide;

(S)-N-(2-(4-(aminomethyl)piperidin-1-yl)-3-fluorophenyl)-4-(2-(methylamino)-6-(3-methylpiperazin-1-yl)pyrimidin-4-yl)-1H-imidazole-2-carboxamide;

4-(6-(4-(aminomethyl)piperidin-1-yl)-2-(methylamino)pyrimidin-4-yl)-N-(2-(4-(aminomethyl)piperidin-1-yl)-3-fluorophenyl)-1H-imidazole-2-carboxamide;

(R)-N-(2-(4-(aminomethyl)piperidin-1-yl)-3-fluorophenyl)-4-(6-(3-aminopiperidin-1-yl)-2-(methylamino)pyrimidin-4-yl)-1H-imidazole-2-carboxamide;

1-(6-(2-(2-(4-(aminomethyl)piperidin-1-yl)-3-fluorophenylcarbamoyl)-1H-imidazol-4-yl)-2-(methylamino)pyrimidin-4-yl)-4-(methylamino)piperidine-4-carboxamide;

(S)-N-(2-(4-(aminomethyl)piperidin-1-yl)-3-fluorophenyl)-4-(6-(3-carbamoyl-3-methoxypyrrolidin-1-yl)-2-(methylamino)pyrimidin-4-yl)-1H-imidazole-2-carboxamide;

(S)-N-(2-(4-(aminomethyl)piperidin-1-yl)-3-fluorophenyl)-4-(6-(3-(cyclohexylcarbamoyl)-3-methoxypyrrolidin-1-yl)-2-(methylamino)pyrimidin-4-yl)-1H-imidazole-2-carboxamide;

(R)-N-(2-(4-(aminomethyl)piperidin-1-yl)-3-fluorophenyl)-4-(6-(3-(benzylcarbamoyl)-3-(methoxymethyl)pyrrolidin-1-yl)-2-(methylamino)pyrimidin-4-yl)-1H-imidazole-2-carboxamide;

(R)-N-(2-(4-(aminomethyl)piperidin-1-yl)-3-fluorophenyl)-4-(6-(3-(cyclopropylcarbamoyl)-3-(methoxymethyl)pyrrolidin-1-yl)-2-(methylamino)pyrimidin-4-yl)-1H-imidazole-2-carboxamide; and

(R)-N-(2-(4-(aminomethyl)piperidin-1-yl)-3-fluorophenyl)-4-(6-(3-(cyclohexylcarbamoyl)-3-(methoxymethyl)pyrrolidin-1-yl)-2-(methylamino)pyrimidin-4-yl)-1H-imidazole-2-carboxamide;

or a pharmaceutically acceptable salt thereof.

13. A pharmaceutical composition comprising a therapeutically effective amount of a compound of claim 1 , or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

14. A compound of claim 1 , or a pharmaceutically acceptable salt thereof for use in treating PDK-1 related cancers.

15. A combination comprising a compound of claim 1 , or a pharmaceutically acceptable salt thereof and an additional anti-cancer agent for simultaneous, separate or sequential use in treating PDK-1 related cancer.

16. A method of treating a disease or disorder characterized by excessive or pathologically elevated cell growth comprising administering a therapeutically effective amount of a compound of claim 1 or a pharmaceutically acceptable salt thereof to a patient in need of such treatment.

17. The method of claim 16 , wherein the disease or disorder is cancer.

18. A method of treating cancer comprising administering a compound of claim 1 or pharmaceutically acceptable salt thereof and an additional anti-cancer to a patient in need of such treatment.